^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tovecimig (CTX-009)

    i
    Other names: CTX-009, ABL 001, NOV1501, TR009, NOV150101, TR-009, ES104, ABL001, HDB001A, HD-B001A, ABL-001, CTX009, CTX 009, ES-104, ES 104, HD B001A, NOV-1501, NOV 1501, NOV-150101, NOV 150101, TR 009
    Company:
    ABL Bio, Compass Therap, Elpiscience, Handok
    Drug class:
    VEGF-A inhibitor, DLL4 inhibitor
    Related drugs:
    1m
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Active, not recruiting, Compass Therapeutics | Completed --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    1m
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=168, Completed, Compass Therapeutics | Active, not recruiting --> Completed | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion • Trial primary completion date
    |
    paclitaxel • tovecimig (CTX-009)
    4ms
    Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=54, Not yet recruiting, Washington University School of Medicine
    New P1/2 trial
    |
    IDH wild-type
    |
    tovecimig (CTX-009)
    12ms
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=49, Completed, Compass Therapeutics | Active, not recruiting --> Completed | N=84 --> 49
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    over1year
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Compass Therapeutics | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    over1year
    CTX-009 with Gemcitabine, Cisplatin, and Durvalumab As First-line Therapy in Patients with Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=50, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • tovecimig (CTX-009)
    over1year
    A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov)
    P1/2, N=41, Terminated, Handok Inc. | N=92 --> 41 | Trial completion date: Jul 2025 --> Jan 2025 | Active, not recruiting --> Terminated; Change of Development Plan
    Enrollment change • Trial completion date • Trial termination
    |
    paclitaxel • irinotecan • tovecimig (CTX-009)
    almost2years
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=150, Active, not recruiting, Compass Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    paclitaxel • tovecimig (CTX-009)
    almost2years
    CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • tovecimig (CTX-009)
    2years
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Compass Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    over2years
    COMPANION-003: A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Recruiting, Compass Therapeutics | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    tovecimig (CTX-009)
    over2years
    A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) (clinicaltrials.gov)
    P2/3, N=150, Recruiting, Compass Therapeutics | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    paclitaxel • tovecimig (CTX-009)